CA
NZ
UK
AU
IND
US
…
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -129.47M | -127.85M | -100.70M | -89.12M | -78.72M |
| Net income | -129.47M | -127.85M | -100.70M | -91.48M | -77.68M |
| Selling general administrative | 33.19M | 28.82M | 25.61M | 25.09M | 22.01M |
| Selling and marketing expenses | - | - | 1.03M | - | - |
| Gross profit | -1.22M | -1.11M | -1.03M | - | - |
| Reconciled depreciation | 1.22M | 1.11M | 1.03M | 0.97M | 0.90M |
| Ebit | -129.47M | -127.85M | -100.70M | -91.77M | -79.77M |
| Ebitda | -128.25M | -126.74M | -99.67M | -81.77M | -78.87M |
| Depreciation and amortization | 1.22M | 1.11M | 1.03M | 10.00M | 0.90M |
| Non operating income net other | - | - | - | - | 0.01M |
| Operating income | -143.00M | -142.90M | -110.78M | -91.77M | -78.87M |
| Other operating expenses | 143.00M | 142.90M | 110.78M | 86.77M | 78.87M |
| Interest expense | - | - | - | 2.65M | 0.14M |
| Interest income | - | - | - | 2.65M | 0.14M |
| Net interest income | - | - | - | 2.65M | 0.14M |
| Non recurring | - | - | - | -5.00M | - |
| Income tax expense | - | - | - | 2.35M | -1.04M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 141.78M | 141.79M | 109.75M | 86.77M | 78.87M |
| Cost of revenue | 1.22M | 1.11M | 1.03M | - | - |
| Total other income expense net | 13.54M | 15.05M | 10.08M | 2.65M | 0.16M |
| Net income from continuing ops | -129.47M | -127.85M | -100.70M | -89.12M | -78.72M |
| Net income applicable to common shares | - | - | - | -89.12M | -78.72M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 411.00M | 274.14M | 254.69M | 247.18M | 298.64M |
| Other current assets | 6.98M | 6.29M | 4.41M | 4.18M | 3.54M |
| Total liab | 26.64M | 31.02M | 30.60M | 24.83M | 25.67M |
| Total stockholder equity | 384.36M | 243.12M | 224.09M | 222.35M | 272.98M |
| Other current liab | 13.26M | 20.11M | 16.76M | 11.41M | 11.34M |
| Common stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.00M |
| Capital stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.00M |
| Retained earnings | -692.24M | -562.77M | -434.93M | -334.23M | -245.11M |
| Other assets | - | - | - | 0.52M | 0.52M |
| Cash | 45.67M | 59.41M | 23.38M | 66.84M | 226.01M |
| Total current liabilities | 20.42M | 24.85M | 20.46M | 15.39M | 15.15M |
| Net debt | -34.12M | -56.22M | -13.17M | -64.18M | -224.08M |
| Short term debt | 3.33M | 3.18M | 2.75M | 2.66M | 1.93M |
| Short long term debt total | 11.55M | 3.18M | 10.21M | 2.66M | 1.93M |
| Other stockholder equity | 1075.81M | 805.51M | 658.75M | 557.87M | 518.18M |
| Property plant equipment | - | - | - | 3.25M | 2.41M |
| Total current assets | 288.47M | 262.25M | 212.60M | 210.46M | 240.52M |
| Long term investments | 110.76M | 0.00M | 26.85M | 21.95M | 43.39M |
| Net tangible assets | - | - | - | 222.35M | 272.98M |
| Short term investments | 235.82M | 196.55M | 184.80M | 139.43M | 10.97M |
| Accounts payable | 3.82M | 1.55M | 0.94M | 1.32M | 1.89M |
| Accumulated other comprehensive income | 0.79M | 0.38M | 0.26M | -1.29M | -0.10M |
| Common stock total equity | - | - | - | 0.01M | 0.00M |
| Retained earnings total equity | - | - | - | -334.23M | -245.11M |
| Non currrent assets other | 0.10M | 8.97M | 0.06M | 11.52M | 12.32M |
| Non current assets total | 122.54M | 11.89M | 42.09M | 36.72M | 58.12M |
| Capital lease obligations | 3.33M | 3.18M | 2.75M | 2.66M | 1.93M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -147.32M | 22.14M | -43.40M | -107.17M | 159.37M |
| Change to liabilities | - | - | - | -1.48M | 2.93M |
| Total cashflows from investing activities | -148.03M | 22.14M | -43.40M | -109.25M | 158.44M |
| Total cash from financing activities | 247.66M | 126.55M | 85.66M | 25.23M | 49.13M |
| Change to operating activities | - | - | - | 1.03M | 1.14M |
| Net income | -129.47M | -127.85M | -100.70M | -89.12M | -78.72M |
| Change in cash | -13.74M | 36.02M | -43.43M | -159.17M | 148.03M |
| Begin period cash flow | 59.90M | 23.88M | 67.31M | 226.47M | 78.45M |
| End period cash flow | 46.16M | 59.90M | 23.88M | 67.31M | 226.47M |
| Total cash from operating activities | -113.37M | -112.66M | -85.69M | -75.14M | -59.54M |
| Issuance of capital stock | 244.37M | 125.00M | 85.00M | 25.00M | 50.00M |
| Depreciation | 1.22M | 1.11M | 1.03M | 0.97M | 0.90M |
| Other cashflows from investing activities | -0.71M | -1.19M | - | - | - |
| Sale purchase of stock | - | - | - | 0.55M | 50.99M |
| Other cashflows from financing activities | 245.26M | 1.55M | 0.66M | -0.32M | -0.87M |
| Change to netincome | - | - | - | 14.50M | 12.86M |
| Capital expenditures | 0.71M | 1.19M | 0.85M | 2.08M | 0.94M |
| Cash flows other operating | - | - | - | 1.03M | 1.14M |
| Cash and cash equivalents changes | - | - | - | -159.17M | 148.03M |
| Change in working capital | -5.46M | 1.97M | 4.90M | -0.45M | 4.07M |
| Stock based compensation | 25.04M | 20.21M | 15.23M | 14.46M | 12.85M |
| Other non cash items | 20.34M | -8.10M | -6.15M | -1.00M | 1.35M |
| Free cash flow | -114.08M | -113.85M | -86.54M | -77.22M | -60.48M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| ORIC Oric Pharmaceuticals Inc |
0.25 2.78% |
9.24 | - | - | - | 3.44 | 0.13 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
240 E. Grand Ave, South San Francisco, CA, United States, 94080
650 388 5600
111
| Name | Title | Year Born |
|---|---|---|
| Dr. Richard A. Heyman Ph.D. | Co-Founder, Independent Chairman & Member of Scientific Advisory Board | 1957 |
| Dr. Jacob M. Chacko M.B.A., M.D. | Pres, CEO & Director | 1979 |
| Mr. Dominic G. Piscitelli CPA, CPA, M.B.A. | Chief Financial Officer | 1975 |
| Dr. Pratik S. Multani M.D., M.S. | Chief Medical Officer | 1967 |
| Dr. Charles L. Sawyers B.A., BA, M.D., Ph.D. | Co-Founder & Member of Scientific Advisory Board | 1959 |
| Dr. Scott W. Lowe Ph.D. | Co-Founder & Member of Scientific Advisory Board | NA |
| Dr. Lori Sickels Friedman Ph.D. | Chief Scientific Officer | 1964 |
| Dr. Christian V. Kuhlen Esq., J.D., M.D. | Gen. Counsel | 1973 |
| Mr. Daniel Iazzetti | VP & Head of People | NA |
| Dr. Edna Chow Maneval | Sr. VP of Clinical Devel. | 1960 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...